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he discovery of antibiotics in 1928 led 
the world to believe that the fight 
against infectious diseases was one to 
be won within a few years. Nowadays, 
nearly 90 years following the discovery of 
penicillin, infectious diseases remain one of 
the main causes of mortality worldwide, with 
lower respiratory tract infections, diarrhoeal 
diseases, and tuberculosis ranking among the 
top 10 causes of death according to the World 
Health Organization (WHO) [1]. In recent 
years, the advent of antibiotic resistance, the 
anti-vaccination movement, and humanitarian 
crises have seen a rise in infectious diseases 
that were once thought to be nearly 
eradicated, such as polio, tuberculosis and 
measles.  
Reducing the burden of infectious diseases by 
2030 is one of the targets stated in the 
Sustainable Development Goals (SDGs), with 
SDG3 focusing on ending the epidemics of the 
Acquired Immune Deficiency Syndrome 
(AIDS), tuberculosis, malaria and neglected 
tropical diseases, as well as combating 
hepatitis, water-borne diseases and other 
communicable diseases [2]. Innovation in the 
field of Science and Technology has allowed 
for better surveillance, diagnosis, and 
treatment options, as well as contributing to 
the development and implementation of 
strategic policies. 
Surveillance 
Formal reports of suspected outbreaks are 
usually received by the WHO from ministries 
of health, national institutes of public health,  
 
WHO regional offices, and civil society. 
Traditional surveillance methods rely on 
routine reporting of pre-determined 
information by healthcare facilities. This 
often results in delayed notifications, making 
outbreak prediction difficult and leading to 
slow or less-than-adequate responses.  
Technological advances, mainly in the field of 
digital transformation, have enabled the 
development of digital surveillance reporting 
systems and monitoring networks, providing 
a more rapid response to epidemic threats. 
These systems collect and analyse 
information obtained from diverse sources, 
including social media, news reports, and 
web-based searches, with the aim of 
detecting events with epidemic potential 
prior to official notifications [3].  
As part of the Global Outbreak Alert and 
Response Network (GOARN), the Global 
Public Health Intelligence Network (GPHIN) 
was developed by Health Canada in 
collaboration with the WHO as a tool for 
event-based surveillance. This system is a 
secure internet-based multi-lingual early-
warning system that continuously searches 
global media sources to identify information 
regarding disease outbreaks and other 
relevant events of potential international 
public health concern. Reports obtained in 
this way require verification to ensure cases 
meet a specific case definition. The 
importance of GPHIN was highlighted in 2003 
during the Severe Acute Respiratory 
Syndrome (SARS) outbreak in China, issuing 
the first alert of unusual respiratory illness in 
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Guangdong Province to WHO and GOARN. 
Diagnosis 
Advances in the field of genetics and 
biotechnology have enabled rapid diagnosis 
of infectious agents. New technologies allow 
the identification of unculturable bacteria 
thanks to DNA sequencing, and whole 
genome sequencing (WGS) can be used not 
only to diagnose an infectious agent but also 
to identify epidemic strains and transmission 
events. The most commonly used genetic tool 
in clinical microbiology is the real-time 
polymerase chain reaction (PCR), which 
amplifies genetic material for enhanced 
detection of pathogens, and is characterized 
by high sensitivity and specificity, low 
contamination risk, and high speed [4].  
A notable example of the role of innovation in 
diagnostics, in the context of infectious 
diseases, is the case of tuberculosis (TB). 
The bacterium that causes TB takes 
approximately 21 days to grow in solid 
culture. Therefore, diagnosis using classical 
microbiology is typically slow, during which 
time the infected patient is contagious and 
can transmit the disease to anyone in close 
proximity, given the airborne nature of TB. In 
addition to genetic techniques as a method of 
identification, the invention of mycobacterial 
growth indicator tubes (MGIT) has been 
revolutionary, allowing identification of 
positive cultures as soon as 1 hour after 
inoculation. Rapid diagnosis leads to better 
treatment outcomes and reduces 
transmission — a key factor in eradication.   
Moreover, innovation in the field of 
diagnostics has not been limited to speed, but 
also to comfort. Many infectious diseases can 
only be diagnosed through a blood sample, 
requiring patients to attend healthcare 
centres and have their blood drawn. 
Advances in the field of HIV/AIDS diagnostics 
have resulted in the invention of HIV home-
tests, allowing people to test for HIV in the 
comfort and privacy of their homes.  
Treatment 
The treatment of infectious diseases consists 
of drugs aimed at killing or limiting the 
growth of the infectious agent, but, due to the 
intense regulatory pathways in drug 
development and the high increased risk of 
failure of clinical trials, pharmaceutical 
companies do not invest greatly in drug 
candidates for infectious diseases since the 
return on investment is generally quite low. 
However, antibiotic resistance is globally 
recognised as an emerging public health 
threat, and policy initiatives are underway to 
provide solutions for overcoming important 
obstacles in the fight against antibiotic 
resistance. These include strategies to 
incentivise the development of novel 
antibiotics, including the development of new 
economic models and policies for sustainable 
antibiotic use [5]. 
‘The fight against infectious disease 
therefore requires a multi-sectorial 
approach; policy makers must 
consider all aspects leading to the 
spread of infection and the specific 
cultural traditions of the affected 
countries.’ 
One of the main causes of antibiotic 
resistance is non-compliance with the 
prescribed treatment due to the length of 
treatment, the amount of daily pills taken, or 
the adverse side effects associated with the 
drug. These problems also arise in treating 
chronic non-bacterial infectious diseases, 
such as HIV. Research from the 
Massachusetts Institute of Technology, as 
well as the Brigham and Women’s Hospital, 
into new delivery options for currently 
available drugs has led to the development of 
an ingestible capsule that can slowly release 
1 week’s worth of antiretroviral drugs [6]. 
Although its application is currently only 
being researched for HIV, this technology 
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could be used in the delivery of a number of 
drugs. 
Policy and its Role in Eradicating Infectious 
Diseases 
Policies on infectious diseases are difficult to 
establish due to the range of competencies 
involved and the different socio-economic 
and cultural settings in which they are 
implemented. Scientific advances have 
played an important role in eradicating many 
infectious diseases in the developed world, 
however, many hard-to-reach areas in low- 
and middle-income countries may not reap 
the benefits of such advances due to high 
levels of poverty. Moreover, poverty creates 
conditions that favour the spread of 
infectious diseases and prevents affected 
populations from obtaining proper access to 
prevention and care. Therefore, policies to 
reduce poverty and inequalities play 
important roles in eradicating diseases.  
The fight against infectious disease therefore 
requires a multi-sectorial approach; policy 
makers must consider all aspects leading to 
the spread of infection and the specific 
cultural traditions of the affected countries. 
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